Boothbay Fund Management’s BriaCell Therapeutics Warrant expiring 2031 BCTXL Stock Holding History
Bought
Maintained
Sold
Other funds holding BCTXL
SM
WAM
Boothbay Fund Management's BCTXL Position: Q2 2026 in Review
Boothbay Fund Management sold out of BriaCell Therapeutics Warrant expiring 2031 (BCTXL) in Q2 2026, closing a stake of 20,000 shares — an estimated $83.8K sold.
Boothbay Fund Management first reported a position in BCTXL in Q1 2026 and held it in 1 quarter. The position peaked at $83.8K in Q1 2026. 10 funds tracked by Wall St. Rank hold BCTXL as of Q2 2026.
- Boothbay Fund Management reported no remaining BriaCell Therapeutics Warrant expiring 2031 position as of Q2 2026 after selling out during the quarter.
- Boothbay Fund Management sold 20,000 BriaCell Therapeutics Warrant expiring 2031 shares in Q2 2026, an estimated $83.8K.
- Boothbay Fund Management first reported a position in BriaCell Therapeutics Warrant expiring 2031 in Q1 2026 and held it in 1 quarter.
- Boothbay Fund Management's BriaCell Therapeutics Warrant expiring 2031 position peaked at $83.8K in Q1 2026.
- 10 funds tracked by Wall St. Rank held BriaCell Therapeutics Warrant expiring 2031 as of Q2 2026.
Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.